Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes by Rushworth, Jo V. & Hooper, Nigel M.
SAGE-Hindawi Access to Research
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 603052, 14 pages
doi:10.4061/2011/603052
Review Article
LipidRafts: LinkingAlzheimer’sAmyloid-β Production,
Aggregation, and Toxicity at NeuronalMembranes
Jo V.Rushworth1 andNigel M. Hooper1,2
1Institute of Molecular and Cellular Biology, Astbury Centre for Structural Molecular Biology,
Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
2Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, LIGHT Laboratories, Clarendon Way,
University of Leeds, Leeds LS2 9JT, UK
Correspondence should be addressed to Nigel M. Hooper, n.m.hooper@leeds.ac.uk
Received 14 October 2010; Accepted 3 November 2010
Academic Editor: Katsuhiko Yanagisawa
Copyright © 2011 J. V. Rushworth and N. M. Hooper. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Lipid rafts are membrane microdomains, enriched in cholesterol and sphingolipids, into which speciﬁc subsets of proteins and
lipids partition, creating cell-signalling platforms that are vital for neuronal functions. Lipid rafts play at least three crucial roles
in Alzheimer’s Disease (AD), namely, in promoting the generation of the amyloid-β (Aβ) peptide, facilitating its aggregation upon
neuronal membranes to form toxic oligomers and hosting speciﬁc neuronal receptors through which the AD-related neurotoxicity
and memory impairments of the Aβ oligomers are transduced. Recent evidence suggests that Aβ oligomers may exert their
deleteriouseﬀectsthroughbindingto,andcausingtheaberrantclusteringof,lipidraftproteinsincludingthecellularprionprotein
and glutamate receptors. The formation of these pathogenic lipid raft-based platforms may be critical for the toxic signalling
mechanisms that underlie synaptic dysfunction and neuropathology in AD.
1.Introduction
Alzheimer’sDisease(AD)isaprogressive,neurodegenerative
brain disorder which aﬀects over 37 million people world-
wide with an estimated global cost of over $600 billion in
2010 [1, 2]. AD is a growing socioeconomic and ﬁnancial
burden due to its strong correlation with ageing; around 1
in 3 people aged over 80 years have AD, which means that
a rapid rise in AD cases is anticipated as life expectancy
continues to increase. Although several therapeutics are
currently available to slow disease progression, there is
currently no way to halt or prevent AD [3].
AD is characterized by the presence of extracellular senile
plaques and intracellular neuroﬁbrillary tangles in the brain.
The major constituents of senile plaques are the amyloid-β
(Aβ) peptides, which are derived from the proteolytic pro-
cessing of the amyloid precursor protein (APP) within lipid
rafts [4]. The Aβ peptide, notably Aβ1−42, is highly aggre-
gation prone and self-assembles to form a heterogeneous
mixture of oligomers and protoﬁbrils, ultimately depositing
asﬁbrilsinsenileplaques.Anaccumulatingbodyofevidence
indicates that soluble Aβ oligomers, which correlate strongly
with disease onset and severity, are the major neurotoxic
s p e c i e si nA D[ 5–8]. Although Aβ oligomers are neurotoxic
at nanomolar concentrations and cause AD-related memory
deﬁcits, the cellular mechanisms of toxicity are poorly char-
acterised.Recently,severalneuronalreceptorswhichbindAβ
oligomers have been identiﬁed, including the cellular prion
protein (PrPC)[ 9] and glutamate receptors [10, 11]a m o n g
others. Interestingly, these receptors reside primarily within,
or partition into, cholesterol-rich microdomains within the
plasma membrane known as lipid rafts.
The three steps which underlie Aβ oligomer-mediated
neuropathology in AD, are (1) Aβ production, (2) Aβ
assembly into oligomers and (3) Aβ oligomers interacting
with neuronal receptors. These steps therefore represent
potential sites of therapeutic intervention in AD. Crucially,
all three of these processes occur in lipid raft domains of
the plasma membrane which are considered to play a key
role in the development of AD [12]. In this paper, we will2 International Journal of Alzheimer’s Disease
outlinethepivotalrolethatlipidraftsplayinlinkingtogether
the generation, self-assembly and toxicity of Aβ oligomers,
which underlie the development of the neuropathology in
AD. A major focus will be upon the interaction between Aβ
oligomers and their putative cellular receptors.
2.LipidRafts
2.1. Lipid Rafts as Essential Neuronal Signalling Platforms.
The multitude of diﬀerent lipids and proteins within the
plasma membrane were once thought to be distributed
homogeneously across the entire lipid bilayer, as proposed
by the ﬂuid mosaic model in 1972 [13]. However, the plasma
membrane is now known to be more akin to a sea of
disordered phospholipids, in which ﬂoat microdomains with
distinct lipid compositions, known as lipid rafts. Lipid rafts
are small (10–200nm), heterogeneous and highly dynamic
assemblies that are enriched in speciﬁc components, namely
cholesterol and sphingolipids (Figure 1)[ 14, 15]. Biochem-
ically, lipid rafts are deﬁned by their relative insolubility in
nonionic detergents at low temperature, conferring upon
them the alternative name, detergent-resistant membranes
(DRMs). Lipid rafts are also known as liquid-ordered
domains because the highly saturated sphingolipid acyl
chains enable closer lipid packing, and therefore more
restricted lateral movement, than the mainly unsaturated
acyl chains of the phospholipids in the surrounding nonraft
regions of the membrane.
Functionally, lipid rafts serve to compartmentalise cel-
lular processes by concentrating certain proteins and lipids
within the same microenvironment. Lipid rafts are par-
ticularly enriched in glycosyl-phosphatidylinositol (GPI)-
anchored and acylated proteins due to the preferential
intercalation of the saturated acyl chains into the liquid-
ordered environment [16]. Other proteins can also associate
with lipid rafts either directly or through binding to other
cofactors or ligands [17]. The dynamic clustering and
pinching oﬀ of lipid rafts regulates the spatial and temporal
assembly of signalling and traﬃcking molecules, forming
short-lived but vital signalling platforms [17]. Lipid rafts are
implicated in various essential cellular functions, including
signal transduction, cell adhesion and protein/lipid sorting
[18]. Of particular relevance here are cell signalling, sorting
and axon guidance, as these processes are essential for neural
development and synaptic plasticity [19, 20]. Crucially,
neuronal lipid rafts are also required for the maintenance
of dendritic spines and healthy synapses, which are vital
for neural communication including learning and memory;
processes which fail in AD [21]. The observation that lipid
rafts are much more abundant in mature hippocampal neu-
rons than in other cell types emphasises their physiological
importance within the memory centre of the healthy brain,
and may explain why hippocampal neurons are a primary
target for Aβ oligomer toxicity and destruction in AD [22].
2.2. Aβ Production Is Lipid Raft Dependent. Lipid rafts
are involved in the regulation of APP processing and the
generation of the Aβ peptide which is the driving force
in AD pathology [23, 24]. For comprehensive reviews
detailing the involvement of membrane rafts in AD and
Aβ production, see [25–27]. The Aβ peptide is produced
by the lipid raft dependent amyloidogenic processing of its
precursor protein, APP (Figure 1)[ 4]. The amyloidogenic
cleavage of full-length APP is initiated by the β-site APP
cleaving enzyme-1 (BACE1), a transmembrane aspartic
metalloprotease. A large, soluble ectodomain (sAPPβ)i s
released to leave behind a membrane-anchored C-terminal
fragment (C99) which retains the intact Aβ sequence.
The second amyloidogenic cleavage of APP involves a γ-
secretase complex which contains presenilin-1 or presenilin-
2 (the catalytic component), presenilin enhancer-2 (PEN2),
nicastrin and anterior pharynx defective-1 (APH1). The
γ-secretase complex cleaves the remaining C99 stub to
release Aβ peptides of between 39–42 residues in length,
depending upon the precise cleavage site, along with the APP
intracellular domain (AICD).
Although the majority of full-length APP is localised
to nonraft regions of the plasma membrane, where non-
amyloidogenic cleavage by the α-secretases ADAM 9, 10,
and 17 [28]p r e c l u d e sA β formation, a subset of both APP
and BACE1 partitions into lipid rafts along with γ-secretase
components. Both BACE1 and the γ-secretase subunits
undergo posttranslational S-palmitoylation which aids their
targeting to lipid raft domains [25]. In the case of APP, a
direct interaction with cholesterol—the major component
of lipid rafts—was recently identiﬁed [29]. High cholesterol
increases the partitioning of APP, along with BACE1 and γ-
secretase components, into lipid rafts [30]. A large body of
evidence points towards lipid rafts being the physiological
site of amyloidogenic Aβ production by BACE1 and the
γ-secretase complex. For example, both the copatching of
APP and BACE1 by cross-linking antibodies [31] and the
exclusive targeting of BACE1 to lipid rafts by the addition
of a GPI-anchor [32] signiﬁcantly increased APP cleavage
at the β-secretase site. Furthermore, enrichments in lipid
raft components, namely cholesterol and ganglioside GM1,
promote the generation of Aβ [31, 33]. All four of the
γ-secretase subunits are also enriched and active within
lipid raft fractions derived from human brain [34, 35]
and lipid raft-type membranes in vitro [36, 37]. In the
brain, the majority of Aβ is found within detergent-resistant,
glycolipid-enriched rafts, along withγ-secretasecomponents
[38].
2.3. Depleting Lipid Raft Components Modulates Aβ Pro-
duction. The composition of lipid rafts puriﬁed from AD
brains has been shown to be abnormal, with the rafts being
more ordered and more viscous [39], which implies that
the modulation of lipid raft composition may present a
therapeutic avenue for modulating AD-related neuropathol-
ogy. This has led to a number of researchers investigating
whether depleting lipid raft components could lower Aβ
production and therefore prevent AD. Cholesterol, being a
major component of lipid rafts and a risk factor for AD, was
the obvious choice to target [40]. For a recent review of the
involvement of cholesterol in AD, see [41].International Journal of Alzheimer’s Disease 3
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Figure 1:Lipidraftsfacilitatetheproduction,aggregation,neuronalbindingandtoxicityofAβ oligomers.(a)TheAβ peptideisproducedby
the lipid raft dependent sequential cleavage of APP, ﬁrst by BACE1 and then by the γ-secretase complex; (b) Lipid raft components including
cholesterol and sialic acid-containing gangliosides promote the aggregation of Aβ to form soluble oligomers; (c) Aβ oligomers bind to
speciﬁc neuronal receptors within pathogenic lipid rafts, including PrPC and the NMDA and mGluR5 receptors. The resulting perturbations
in neuronal function and survival underlie the memory impairments and cognitive decline which characterise Alzheimer’s disease.
Cholesterol depletion has indeed been shown to reduce
APP partitioning into lipid rafts which precludes its interac-
tion with BACE1 and γ-secretase components, thus lowering
Aβ production [42]. Hypercholesterolaemia is linked to
increased Aβ production and deposition in the brain, both
in humans [43–45] and in rodents [46–48] and is linked to
an increased risk of developing AD. Cholesterol depletion
also lowers Aβ production in cultured cells [31]a n do n e
study showed that a 70% reduction in cholesterol in living
hippocampal neurons was suﬃcient to completely abolish
Aβ production [49].
Taking this into account, cholesterol-lowering drugs
known as statins have been evaluated as potential anti-
AD drugs, with conﬂicting results [50]. Some retrospective
epidemiological studies have shown that the administration
of statins, which lower cholesterol levels, can reduce the
incidence of dementia, including AD [51–53]. Cholesterol
inhibitorscanalsolowerAβ levelsinculturedneuroblastoma
cells [54]. However, other studies have shown no correlation
between statin usage and dementia [55] and the eﬀect
of statins upon disease progression and cognitive decline
in AD patients has been challenged [56]. Intriguingly, it
was revealed recently that Aβ production actually reduces
cholesterol in cultured cells of neuronal origin by increasing
eﬄux, possibly acting as a chaperone to remove excess
cholesterol from the brain to the circulation [57].
Although a reduction in cholesterol may go some way
towards reducing Aβ levels in the brain, much longer-term
epidemiological studies and clinical trials initiated before
signiﬁcant neuronal loss and cognitive function are apparent
are required in order to further elucidate the eﬀects of low-
ering cholesterol levels upon AD onset and neuropathology.
Lipid rafts contain many essential components other than
cholesterol, such as sphingolipids, and it is likely that the
modulation of just one factor will not completely abolish
Aβ production in vivo. It is important to remember that
cholesterol metabolism in the brain is largely isolated from
the rest of the body by the blood-brain barrier. As nearly
all of the cholesterol in the brain is synthesised in situ, the
modulation of cholesterol levels within neurons represents a
more diﬃcult pharmaceutical challenge and the blood-brain
barrierpermeabilityofthedrugsusedneedstobeconsidered
[29]. Furthermore, even if cholestxerol depletion mediates
ar e d u c t i o ni nA β levels, Aβ oligomers eﬀect neurotoxicity
and memory impairments at low nanomolar concentrations
[58]. Therefore, residual levels of Aβ production may be
suﬃcient for continued Aβ oligomer-mediated toxicity.
3. LipidRaft Components PromoteAβ
Oligomerisation
3.1. Aβ Oligomers Are the Major Neurotoxic Species in AD.
The Aβ peptide is natively unfolded and, under certain
conditions, it aggregates to form a heterogeneous mixture
of soluble oligomers, protoﬁbrils and ﬁbrils. It was accepted
for a long time that the Aβ ﬁbrils that deposit in neuritic
plaques, which are observed post mortem in diseased brains,
were responsible for neurotoxicity in AD [59]. Aβ ﬁbrils
have been reported to induce neuronal dysfunction and4 International Journal of Alzheimer’s Disease
cell death, although ﬁbrils are less potent neurotoxins than
soluble forms of Aβ [60, 61]. Interestingly, ﬁbrils have been
found to become more neurotoxic upon fragmentation [62],
raising the possibility that soluble species released from
ﬁbril ends may underlie their neurotoxicity. A plethora of
studies have now demonstrated that levels of soluble Aβ
oligomers in the brain correlate much better than plaques
or ﬁbrils with AD onset, progression and severity [5, 6,
8, 63, 64]. Within the last ﬁfteen years, a large number
o fs t u d i e sf r o mr e s e a r c hg r o u p sw o r l d w i d eh a v er e p o r t e d
the existence of many diﬀerent oligomeric assemblies from
various sources, including AD brain and cerebrospinal ﬂuid
(CSF) samples, secreted into the conditioned medium of
cultured cells or prepared artiﬁcially from recombinant
or synthetic Aβ peptides [65]. A heterogeneous range of
sizes and peptide conformations have been observed among
these natural and artiﬁcial Aβ oligomers, including dimers
and trimers [66, 67], tetramers, hexamers and the dode-
cameric Aβ∗56 [64], globulomers [68], ring-shaped annular
protoﬁbrils [69] and higher molecular weight Aβ-derived
diﬀusible ligands (ADDLs) which can comprise hundreds
of monomeric subunits [9, 70]( Figure 2). However, despite
the disparity in size and source, Aβ oligomers appear
to share important functional properties. Notably, both
natural and synthetic Aβ oligomer preparations bind to
hippocampalneuronsandcellsofneuronallineage,causinga
loss of dendritic spines, neurotoxicity, the inhibition of long-
term synaptic potentiation (LTP: an electrophysiological
correlate of learning and memory) and impairments in
working memory at nanomolar concentrations [64, 67,
68, 70–73]. The preferential binding and toxicity of Aβ
oligomers towards neurons in the hippocampus may explain
why Aβ oligomers correlate with AD severity and disease
progression [9, 68, 70]. However, the cellular mechanisms
by which these eﬀects are modulated remain poorly under-
stood.
3.2. Aβ Oligomerisation Is Modulated by Lipid Raft Com-
ponents. Aβ is a physiological peptide which is present in
the brain tissue and CSF of healthy subjects throughout
life, without necessarily causing neurodegeneration [74–76].
Many studies have shown that monomeric, nonaggregated
Aβ does not cause the neurotoxic eﬀects that are mediated
by Aβ oligomers. In fact, monomeric Aβ has recently been
reported to have neuroprotective roles in the brain [77, 78].
The aggregation of Aβ is necessary for its toxicity [79]a n d
the emerging picture is that soluble Aβ oligomers are the
proximate neurotoxins in AD [8, 80]. The aggregation of
Aβ is therefore a critical step in the development of AD
pathogenesis, and one in which lipid rafts appear to play a
fundamental role.
Neuronal sensitivity to Aβ-induced toxicity has been
found to be dependent upon Aβ binding to the cell
membrane [81]a n dA β has been identiﬁed in lipid rafts
from cultured cells and from human and rodent brains.
Soluble Aβ dimers accumulate rapidly, and have been found
at elevated levels, in lipid raft fractions isolated from human
and transgenic mouse model AD brains [82]. Importantly,
Aβ has been shown to accumulate in presynaptic terminals
in AD cortex where it colocalises with the lipid raft markers
cholesterol and ganglioside GM1 [83]. Taken together, these
data suggest that Aβ accumulation and aggregation within
lipid rafts may underlie AD neuropathology.
As cholesterol is a major component of lipid rafts, it
was postulated to facilitate Aβ oligomerisation on neuronal
membranes.Thebrainisparticularlyenrichedincholesterol,
harbouring over 23% of the body’s total complement but
comprising only around 2% of total body mass [84].
However, the role of cholesterol in promoting the assembly
of Aβ is controversial and conﬂicting evidence has been
presented in recent years. The main diﬃculty is being
able to distinguish between the key role of cholesterol in
building the lipid raft domains necessary for Aβ production
and the suggested role of cholesterol in promoting Aβ
oligomerisation. As discussed previously, raised cholesterol
has been linked to AD; is this solely due to an increase in
total lipid raft composition of the plasma membrane which
increases amyloidogenic processing of APP to yield more Aβ
peptide or due to a direct eﬀect on Aβ oligomerisation?
A growing body of evidence suggests that certain compo-
nents of lipid raft domains may play a much more sinister
role in catalysing the conversion of the aggregation-prone
Aβ peptide to its neurotoxic, oligomeric states. Cholesterol
is known to modulate the interaction of the Aβ peptide
with lipid bilayers [85]. Further, Aβ oligomers isolated from
AD patients associate with DRMs in a cholesterol-dependent
manner, and cholesterol depletion reduces the aggregation
of Aβ [86]. It is currently unknown, however, whether
this latter eﬀect is due to a direct interaction between Aβ
and cholesterol, or due to the overall depletion in lipid
raft domains and/or the subsequent change in composition
and properties brought on by a reduction in cholesterol.
Conversely, a recent study revealed that increasing the level
ofcholesterolinhumanneuroblastomacellsactuallyreduced
the ability of synthetic Aβ oligomers to bind [87], in spite
of the colocalisation of the Aβ oligomers with the lipid
raft component ganglioside GM1. These data agree with
the authors’ previous ﬁnding that an increased level of
membrane cholesterol exerts a protective eﬀect against Aβ
oligomer toxicity [88]. In the more recent study [89]i tw a s
proposed that a ﬂuctuation in cholesterol levels may alter
the physical properties of lipid rafts thereby modulating
oligomer binding.
Cholesterol can also facilitate Aβ aggregation through
the structural modiﬁcation of other lipid raft components.
A recent study using reconstituted membranes revealed
a structural role for cholesterol in modulating the con-
formation of glycosphingolipids. Depending on the type
of glycosphingolipid, cholesterol can either facilitate (such
as for ganglioside GM1) or inhibit the interaction of
Aβ peptides with lipid rafts through ﬁne-tuning of the
glycosphingolipid conformation [90]. This reinforces the
notion that Aβ binding to, and aggregation upon, neuronal
lipid raft domains cannot be ascribed to a single component,
but rather that multiple players are likely to be involved.
In fact, mounting evidence suggests that gangliosides
within lipid rafts appear to be the main driving forceInternational Journal of Alzheimer’s Disease 5
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Figure 2: Aβ oligomers are the key neurotoxic assemblies in Alzheimer’s Disease. The Aβ peptide is natively unfolded yet conformationally
plastic and prone to aggregation. In response to various stimuli, including elevated concentration, Aβ undergoes complex conformational
rearrangements to form oligomer-competent or ﬁbril-competent intermediates. A variety of Aβ oligomers can form which include low-n
oligomers (dimer and trimers), globulomers, hexameric and dodecameric (Aβ∗56) states, higher molecular weight species such as Aβ-
derived diﬀusible ligands (ADDLs) and ring-shaped annular protoﬁbrils (APFs). Some oligomers are stable, oﬀ-pathway intermediates
whereas others undergo further conformational changes and aggregation to form larger protoﬁbrils and ﬁbrils. Fibrils of Aβ are insoluble
and deposit within extracellular senile plaques. Aβ oligomers are soluble and represent the active neurotoxic species in AD. The speciﬁc
binding of Aβ oligomers to neurons, particularly in the hippocampus, triggers the memory impairments, loss of synaptic functionality and
neuronal death which characterise AD.
behind the oligomerisation of Aβ on neuronal membranes.
The development of AD within certain brain regions
has been found to correlate with increased ganglioside
levels [91]. Gangliosides are glycosphingolipids with one
or more sialic acid moieties attached to the sugar chain.
Gangliosides are found predominantly in the central ner-
vous system, where they are enriched in lipid rafts due
to the preferential packing of their saturated acyl chains
within the liquid-ordered phase. A study in 1995 revealed
that a population of membrane-bound Aβ tightly bound
to gangliosides exists in AD brains [92]. More recently,
exogenously-applied Aβ was shown to bind to neuronal
membranes and to redistribute into lipid rafts where it
colocalised with ganglioside GM1 in a time-dependent
manner [93]. GM1 facilitated the binding and accumulation
of Aβ oligomers at lipid raft domains and appeared to be
required for the Aβ oligomer-mediated lipid peroxidation
of DRMs [94]. Ganglioside GM1 contains just one sialic
acid moiety and plays important physiological roles in
neuronal function. Aβ appears to interact with the sialic
acid moiety of gangliosides such as GM1 and these bound
a g g r e g a t e sc a ng oo nt os e e df u r t h e rA β aggregation [95].
The interaction between sialic acid and Aβ induces a
conformational rearrangement of the Aβ peptide chain [96]
which may potentiate Aβ oligomerisation. DRMs derived
from ganglioside-rich rat brain, but not from liver, were
found to promote the oligomerisation of Aβ [97]. Further,
this study revealed that the removal of cholesterol or protein
from these raft fractions did not prevent Aβ aggregation,
providing evidence that neither cholesterol nor protein
is essential for this process. However, lipid raft fractions
containing very low levels of gangliosides still retained
some Aβ oligomerisation ability, and therefore ganglioside-
independent aggregation mechanisms cannot be ruled out.
4. Aβ OligomersBindtoNeuronalReceptors
withinLipidRafts
4.1. Aβ Oligomers Bind to High Aﬃnity Protein Receptors.
When the ﬁrst synthetic Aβ oligomers were prepared from
Aβ1−42 peptide by the Klein laboratory in 1998, it was
observed that their binding to hippocampal neurons and
cultured nerve cells was abolished by treating the cells with
trypsin [70]. This, coupled with the low oligomer concentra-
tion (5nM) required for neurotoxicity, implied that speciﬁc
protein receptors were responsible for the binding of Aβ
oligomers and for the subsequent transduction and ampliﬁ-
cation of neurotoxicity. Indeed, a recent study found that Aβ
oligomerbindingtoneuronswassaturablewithanestimated
apparent Kd of ∼0.4nM [9]. This ﬁnding implied that one or
more high-aﬃnity receptors are responsible for Aβ oligomer
binding and subsequent neurotoxicity. Immunoﬂuorescence
microscopy has revealed that Aβ oligomers bind to dendritic
spines of hippocampal neurons where they colocalise with
postsynaptic markers [9, 98, 99]. Interestingly, Aβ oligomer
bindingtoneuronshasapunctateappearance[100],whichis
reminiscent of the appearance of lipid raft localised proteins
[101]. Several putative neuronal receptors for Aβ have been
identiﬁed in recent years, namely proteins that are related to
mechanisms of memory and neuroprotection in the brain.
Noteworthy, all of these receptors either reside primarily
within, or can partition into, lipid raft domains at the
surface of neurons. Lipid rafts may therefore hold the key to6 International Journal of Alzheimer’s Disease
understanding how the deleterious eﬀects of Aβ oligomers
are transduced through binding to speciﬁc receptors within
these microdomains.
4.2. The Cellular Prion Protein (PrPSc). In 2009, Laur´ en and
colleagues reported that the cellular prion protein (PrPC)i sa
speciﬁc,high-aﬃnityneuronalreceptorforAβ1−42 oligomers
[9]. PrPC is a GPI-anchored protein that is expressed at high
levels in the brain, particularly at synapses and axons, where
it resides in lipid rafts. The misfolded form of the prion
protein (PrPSc) is infamous for being the causative agent
in Mad Cow Disease (Bovine Spongiform Encephalopathy,
BSE) and its human equivalent, Creutzfeldt-Jakob Dis-
ease (CJD). Although the correctly-folded PrPC is critical
for prion disease pathogenesis, its physiological function
remains enigmatic, with potential neuroprotective roles in
oxidative stress defence, metal ion homeostasis and anti-
apoptosis [102]. In a search to identify neuronal receptors
for Aβ oligomers, Laur´ en et al. [9] screened a mouse brain
expression library of 225,000 cDNA constructs from which
only two positive clones, both encoding full-length PrPC,
were isolated that were able to bind Aβ oligomers with high
aﬃnity and speciﬁcity. Interestingly, the PrPC homologues
Shadoo and Doppel were found not to bind Aβ oligomers
to any signiﬁcant degree. A further, more focussed screen
of 352 clones encoding transmembrane proteins identiﬁed
amyloid-β precursor-like protein 1 (APLP1) and trans-
membrane protein 30B (TMEM30B) as weak Aβ receptors,
although their speciﬁcity for oligomeric Aβ was poor. The α7
nicotinic acetylcholine receptor (nAChRα7) and the receptor
f o ra d v a n c e dg l y c a t i o ne n dp r o d u c t s( R A G E )w e r ea l s o
assayed due to their previously reported aﬃnities for Aβ
peptides [103, 104], although neither displayed high-aﬃnity
Aβ oligomerbinding.Therefore,PrPC wastheonlyidentiﬁed
receptor to display both high aﬃnity and high speciﬁcity for
Aβ oligomers.
A direct interaction between PrPC and Aβ oligomers was
conﬁrmed and the core oligomer binding region of PrPC
was narrowed down to amino acids 95–110, a positively
charged cluster rich in lysine residues [9]. PrPC was also
shown to mediate the inhibition of LTP that is induced
when hippocampal slices were incubated with Aβ oligomers
at nanomolar concentrations [9]. A follow-up in vivo study
revealed that the presence of PrPC is required for the Aβ
oligomer-mediated memory impairments in an AD model
mouse [105]. Taken together, these data indicate a strong
association between Aβ oligomers binding to PrPC within
lipid rafts of hippocampal neurons and the induction of
memory deﬁcits that are characteristic of AD.
Nevertheless,therehasbeensomedisputeovertheroleof
PrPC in transducing the deleterious eﬀects of Aβ oligomers
in vivo, as other studies have reported data which oppose this
theory. First, Balducci and colleagues reported that although
Aβ oligomers bind tightly to PrPC they cause impairments
in long-term memory in mice independently of PrPC [106].
Inthisstudy,theeﬀectsofsyntheticAβ oligomersuponwild-
typemicewereobserved,whereasGimbeletal.[72]utiliseda
mouse model expressing a familial AD mutant APP. Further,
the synthetic depsipeptide and the oligomer preparation
method utilised by Balducci et al. [106]d i ﬀered from those
used by Gimbel and coworkers [72], raising the possibility
that PrPC does not have the same binding aﬃnity for all
types of Aβ oligomers. Second, the Aguzzi group crossed
an AD mouse model, which suﬀers from Aβ-dependent
memory deﬁcits in the form of LTP impairment, with mice
expressing either wild-type PrPC,as e c r e t e df o r mo fP r P C
(lacking its GPI anchor) or no PrPC [107]. They found that
thepresenceorabsenceofwild-typePrPC hadnoeﬀectupon
the Aβ-mediated inhibition of LTP. However, expression
of the secreted form of PrPC was found to suppress the
impairment in LTP, which the authors proposed may be due
to the potential chelation and subsequent degradation of Aβ
oligomers by soluble PrPC in the extracellular milieu. Third,
Kessels and coworkers reported the inﬂuence of PrPC upon
hippocampal neurons expressing a C-terminally truncated
form of APP in a viral expression construct [108]. The same
loss of dendritic spines and inhibition of LTP were observed
in the presence and absence of PrPC, suggesting that Aβ-
mediated synaptic defects do not require PrPC.H o w e v e r ,
Laur´ en and colleagueshave emphasised the diﬀerences in the
modelsystemutilisedbyKesselsandcoworkersintheirstudy
which may account for the opposing data, namely the viral
expression of APP, a higher concentration of Aβ oligomers
and a diﬀerence in the observed suppression of synaptic
plasticity [109].
Further investigation is needed to clarify the role of PrPC
in modulating the Aβ oligomer-mediated impairments in
memory and LTP. Diﬀerences in the oligomer preparations,
age and genotype of the mouse models, the nature of
the promoter elements driving gene expression and the
particular memory tests employed by the diﬀerent authors
may account for the discrepancies in the data.
The binding of Aβ oligomers to PrPC is not the ﬁrst
time that PrPC has been linked to AD. Senile plaques from
a subset of AD patients were observed to contain PrPC [110]
and abundant Aβ deposits have been observed in some CJD
cases [111]. Furthermore, the Met/Val 129 polymorphism
in the PRNP gene that encodes PrPC is a risk factor for
early-onset AD [112]. In 2007, we demonstrated that PrPC
negatively modulates Aβ production through inhibition of
the APP cleaving enzyme, BACE1 [113]. These data, along
with the recent discovery that PrPC binds to Aβ oligomers
and transduces their deleterious eﬀects, raises the intriguing
possibility of a feedback loop [114]. We propose that,
physiologically, PrPC maintains Aβ production at a low level
throughBACE1inhibition,butinADthisinteractionmaybe
disrupted by Aβ oligomers binding to PrPC and causing its
segregation from BACE1. Therefore, Aβ oligomers binding
to PrPC may also promote their own production through
the ablation of BACE1 inhibition by PrPC.M o r er e c e n t l y ,
levels of PrPC have been shown to be reduced in AD brains
[115, 116] possibly arguing against PrPC being involved in
mediating the neurotoxic eﬀects of Aβ oligomers, at least in
the terminal stages of the disease.
It is important to note that Laur´ en and colleagues
reported that the removal of PrPC from hippocampal
neuronsonlyreducedAβoligomerbindingbyapproximatelyInternational Journal of Alzheimer’s Disease 7
50% [9]. This suggests that other receptors not identiﬁed
in the expression library screen due to nonpreferential
binding conditions or a low aﬃnity for the particular type
of Aβ oligomers that were used, and/or nonprotein lipid
raft components, may play equally crucial roles in Aβ
oligomer binding and neurotoxicity. Glutamate receptors,
which possibly exist in a complex with PrPC [117], represent
acandidateinteractingpartnerforAβ oligomerswhichcould
explain the deleterious eﬀects upon hippocampal synaptic
plasticity.
4.3. Glutamate Receptors. Synaptic failure and impairments
in synaptic plasticity are hallmarks of early AD neuropathol-
ogy [100, 118, 119]. LTP and long-term depression (LTD)
are mechanistic dimmer switches which facilitate synaptic
plasticity by strengthening or weakening communication
across a synapse, respectively, with LTP being essential for
hippocampal-dependent learning and memory [120, 121].
Numerous lines of study have conﬁrmed that soluble Aβ
oligomers from various sources, including those isolated
from AD brains, disrupt hippocampal LTP in vitro and in
vivo and cause impairments in learning and memory [9, 67,
70, 107, 122, 123]. Although not all studies agree, it has
also been demonstrated that Aβ oligomers can provoke LTD
which opposes LTP [67, 124, 125]. Neuronal receptors which
modulate LTP and/or LTD are therefore likely candidates for
the speciﬁc binding of Aβ oligomers. Glutamate receptors
are central to the modulation of LTP and LTD. Additionally,
glutamate receptor dysfunction has been implicated in
AD which is characterised by memory deﬁcits caused by
impaired synaptic plasticity [126]. Glutamate receptors con-
sist of two classes; ionotropic (cation-speciﬁc ion channels)
and metabotropic (G-protein-coupled). Members of both
classes have been implicated as neuronal receptors for Aβ
oligomers.
4.3.1. NMDA Ionotropic Glutamate Receptors. N-methyl-D-
aspartate receptors (NMDARs) constitute a major class of
glutamate receptors in the mammalian brain which localise
to the postsynaptic membrane of excitatory synapses [127].
These ion channels play key roles in excitatory synaptic
transmission and synaptic plasticity [128]. The membrane
channel is usually blocked by Mg2+ ions which are displaced
when synaptic transmission results in depolarisation and
glutamate release and binding. NMDAR channel opening
leads to the rapid inﬂux of Ca2+ which triggers LTP induc-
tion [129]. Longer-term eﬀects which maintain the rein-
forced synapse include the activation of α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptors (AMPARs),
altered gene expression and kinase activity and the growth of
new dendritic spines. Interestingly, NMDAR activation can
also stimulate LTD, having the opposing eﬀect of synapse
weakening, and this appears to depend upon the nature of
the stimulus and the subtype of NMDAR involved [130].
NMDARs localise to lipid raft domains where they
interact with ﬂotillins [131, 132] although they can move
laterally between raft and nonraft domains in response to
cues including phosphorylation [133]. Statins, which deplete
cellular cholesterol thus reducing lipid raft formation, have
been shown to reduce the localisation of NMDARs to lipid
raft domains, which has a neuroprotective eﬀect [134].
Mounting evidence points towards a central role for
NMDARs in the modulation of Aβ oligomer toxicity. Soluble
Aβ oligomers inhibit NMDAR-dependent LTP [70, 135]
and exhibit postsynaptic binding to hippocampal neurons
which express NMDAR subunits GluN1 and GluN2B [100].
A reduction in NMDAR subunits GluN1 and GluN2B has
previously been observed in the hippocampus of AD brains
[136]. Crucially, a recent study has conﬁrmed that Aβ
oligomer-mediatedearlysynapticdysfunctiondependsupon
the activation of GluN2B-containing NMDARs [10]. Aβ
oligomers were found to decrease the NMDAR-dependent
inﬂux of Ca2+ into dendritic spines [137], and to reduce
dendritic spine and synapse density [10] in a mechanism
which involve the subsequent phosphorylation of tau [138].
NMDAR antagonists, including one which is speciﬁc for
GluN2B subunits, were able to reverse the Aβ-induced loss
of dendritic spine density [100, 137, 139]. These eﬀects
are consistent with Aβ oligomers blocking the NMDAR-
mediated stimulation of LTP whilst promoting NMDAR-
mediatedLTD.Inaddition,Aβoligomershavebeenshownto
stimulate the excessive generation of reactive oxygen species
(ROS) through an NMDAR-dependent mechanism [140],
suggesting a link between aberrant ROS regulation and Aβ-
induced cognitive impairment.
Furthermore, evidence to conﬁrm a direct interaction
between Aβ oligomers and NMDAR subunits has recently
been presented. Partial colocalisation was observed between
NMDAR GluN2B and Aβ oligomers in hippocampal slices,
which increased upon the addition of glutamate, although
the maximum colocalisation was less than 50% [141].
Further, Aβ oligomers were recently found to coimmuno-
precipitate with NMDAR subunits [117]. However, an
indirect model proposed by Venkitaramani and colleagues
suggeststhattheAβ oligomer-mediateddecreaseinGluN2B-
containing NMDARs results from the former binding to
α-7 nicotinic acetylcholine receptors (α7nAChR), which
activates striatal-enriched tyrosine phosphatase (STEP), in
turn stimulating NMDAR internalisation [142]. More recent
datahasrevealedelevatedlevelsofSTEPinamousemodelof
AD and in human AD brains, and that the removal of STEP
abrogates the Aβ-mediated reduction in NMDARs at the cell
surface [143] .W h e t h e ro rn o tA β oligomers interact with
NMDARs directly, growing evidence suggests that NMDARs
play an important role in transducing the deleterious eﬀects
of Aβ oligomers upon synaptic functionality.
4.3.2. mGluR5 Metabotropic Glutamate Receptor. The
mGluR5 metabotropic glutamate receptor plays important
regulatory roles in neuronal calcium mobilisation and the
modulation of LTP and excitatory postsynaptic potentials
in hippocampal neurons [144, 145]. Recently, mGluR5 was
identiﬁed as a novel Aβ oligomer receptor in a study of
the behaviour of ﬂuorescently-labelled Aβ oligomers on
hippocampal neurons and their interaction with neuronal
receptors [117]. The Aβ oligomers bound to excitatory8 International Journal of Alzheimer’s Disease
synapses where their mobility decreased as they aggregated
to form larger clusters over time. Consistent with previous
data, Aβ o l i g o m e r sc a u s e dar e m o v a li nN M D A R sf r o m
synapses and were found to coimmunoprecipitate with
NMDAR subunits. Interestingly, the Aβ oligomers also
formed complexes with mGluR5 receptors, which caused
their lateral redistribution into dendritic spines followed by
Ca2+ dysregulation. Renner and colleagues also observed
a time-dependent increase in lipid raft-localised mGluR5s
which suggests that Aβ oligomers reduce the mobility
of mGluRs, causing their aberrant aggregation within
pathological signalling platforms [117]. When mGluR5 was
removed from mouse hippocampal neurons, Aβ oligomer
binding was reduced by approximately 80% and the loss of
NMDARs from the cell surface was prevented.
Metabotropic glutamate receptors have been implicated
previously in the pathogenesis of AD and other neurode-
generative disorders [126].Impaired mGluRsignalling inthe
cortex of AD patients has been shown to correlate with AD-
related neuropathological changes [146]. Interestingly, the
stimulation of mGluRs can modulate APP processing [147].
A recent study revealed that the Aβ peptide upregulates the
expressionofmGluR5sinastrocytes,protectivenonneuronal
cellswhichareimplicatedinADpathogenesisandinﬂamma-
tion [148]. Increased levels of mGluR5s were observed in the
brains of Down’s syndrome patients [149]; a disease in which
elevated levels of Aβ result from the triplication of the APP
gene [150].
4.3.3. Other Putative Receptors. Various other lipid raft-
associated proteins have been reported to eﬀectAβ-mediated
synaptic dysfunction. For instance, the removal of nerve
growth factor receptors (NGFRs), including TrkA and p75
neurotrophin receptor, from cells treated with GM1-induced
Aβ oligomers caused a signiﬁcant reduction in oligomer-
mediated cytoxicity [151]. NGFR dysfunction and aberrant
NGF signalling is associated with AD and increased Aβ
production [152, 153]. Although no direct interaction has
been shown to our knowledge, it is possible that interplay
between Aβ oligomers and NGFRs may form part of a
positive feedback loop which serves to reinforce Aβ oligomer
production, whilst blocking NGF signalling with deleterious
eﬀects upon neuronal survival. Physiologically, NGF binds
to TrkA causing the translocation and clustering of receptors
within lipid rafts [154]. The binding of Aβ oligomers to TrkA
and other NGFRs may therefore cause aberrant lipid raft
clustering which prevents or disrupts the formation of the
normal signalling platforms.
Recent research proposes that impaired insulin signalling
may be involved in AD, even leading to the hypothesis
that AD represents a third type of diabetes [155]. Insulin
receptors, which are robustly expressed in hippocampal
neurons, were found to bind Aβ oligomers and to undergo
internalisation from dendritic spines [156]. Perturbations
in insulin signalling in the brain caused by Aβ oligomers
may impair memory and LTP [157]. Interestingly, insulin
receptor subunits are also enriched in lipid raft domains in
hippocampal neurons [158].
4.3.4. Multireceptor, Pathogenic Signalling Platforms Are
Induced by Aβ Oligomers. The emerging picture is that lipid
rafts accommodate multiple receptors for Aβ oligomers,
namely PrPC along with NMDAR, mGluR5 and possibly
other, lower aﬃnity receptors. Interestingly, there is evidence
to suggest that these three lipid raft-associated receptors
interact together. Metabotropic glutamate receptors have
been found to cocluster with NMDARs [159]. It has
also been reported that PrPC inhibited NMDAR function
in hippocampal neurons and coimmunoprecipitated with
NMDAR subunits [160]. The functional and physical links
between these Aβ oligomer receptors suggest the existence
of a multi-component, Aβ oligomer binding raft complex,
comprising of PrPC, mGluR5 and NMDAR (Figure 3)
[117]. Whether the formation of this complex is required
for oligomer binding, or whether the interaction of Aβ
oligomers with the individual proteins induces its assembly,
is a “chicken and egg” situation. One possible hypothesis
is that Aβ oligomers promote the clustering of PrPC and
glutamate receptors into pathological mega-scaﬀolds which
induce both toxic loss- and gain-of-function downstream
eﬀects. For instance, the aberrant localisation of glutamate
receptors may impede neuronal signalling mechanisms
including LTP, while the clustering or internalisation of
NMDARs may promote their LTD-inducing functionality.
The combined eﬀects of oligomer binding upon more than
one glutamate receptor is likely to be a large disturbance
in Ca2+ homeostasis which results in pathological sig-
nalling cascades. Interestingly, the PrPC-mediated response
to oxidative stress is thought to induce signalling cascades
which can modulate Ca2+ ﬂux and synaptic plasticity [161].
Furthermore, Aβ oligomers may cause the internalisation or
loss of function of components such as PrPC thus reducing
neuroprotection against oxidative stress at the cell surface.
The clustering of Aβ oligomers at lipid raft domains may
also cause damage to physiologically important signalling
rafts,thusimpairingneuronalfunction.Furthermore,theAβ
oligomer-induced redistribution of neuronal proteins into
lipid rafts may inﬂuence their nonraft interacting partners,
with additional deleterious eﬀects upon neuronal function
and integrity.
5. Conclusions
Neuronal lipid rafts are crucial modulators of Aβ production
and aggregation, leading to the accumulation of neurotoxic
Aβ oligomers in the brain which drive AD pathology.
Recent evidence now incriminates lipid rafts as pathological
signalling platforms in which Aβ oligomer receptors, such as
PrPC and glutamate receptors, cluster. Aβ oligomer binding
appears to induce the aberrant localisation of these proteins
with deleterious eﬀects upon their physiological functions
including hippocampal LTP, which underlies memory, and
defence against oxidative stress. In this way, lipid rafts
appear to be directly responsible for the transduction of Aβ
oligomer-mediated memory impairments and neurotoxicity
which characterise AD. Lipid rafts are not only implicated in
AD but may also be the key to a range of neurodegenerativeInternational Journal of Alzheimer’s Disease 9
Non-raft Normal lipid raft
PrPC mGluR5 NMDAR
Physiological
functions
Aβ
(a) Normal
Non-raft Pathogenic lipid raft
Toxic signals
PrPC mGluR5 NMDAR Aβ
(b) Alzheimer’s disease
Figure 3: Aβ oligomer binding stimulates the clustering of speciﬁc neuronal receptors into aberrant pathogenic signalling platforms
at the synapse. (a) Synaptic function and neural communication is maintained by the activity of postsynaptic receptors including the
neuroprotectivePrPC andtheNMDAandmGluR5glutamatereceptors,whichmodulatesynapticplasticity.Inthehealthybrain,thedynamic
translocation of such receptors between lipid raft and nonraft domains of the plasma membrane modulates their activities; (b) in AD,
the binding of Aβ oligomers at postsynaptic membranes causes the redistribution and clustering of receptors including PrPC,N M D A R
and mGluR5 into pathological signalling platforms [117]. The resulting loss of transient lateral movement and subsequently interaction
with other components is proposed to cause a loss of normal functionality combined with aberrant signalling by these receptors. The
dysregulation of Ca2+ and inhibition of synaptic long-term potentiation likely underlie the memory deﬁcits which characterise AD. Further,
the loss of PrPC depletes neuronal protection against oxidative stress which may partially account for the neuronal death that is observed in
AD brains.
proteinopathies,includingParkinson’sDisease,Huntington’s
Disease, amyotrophic lateral sclerosis and prion diseases
(reviewed in [12]). Indeed, lipid raft disruption protects
neurons against the toxicity of other oligomers besides Aβ
[22]andlipidraftsmaythereforerepresentgenericplatforms
for oligomer-mediated neurotoxicity. Understanding the cell
biology of the downstream eﬀects of amyloid oligomers
bindingtoneuronallipidraftproteinsmayuncoverpotential
therapeutic targets for the prevention of AD and other
neurodegenerative diseases.
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